Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PURETHAL Birch Rush Up-dosing Regimen
NCT01918956Phase 4Completed
- Sponsor
- HAL Allergy Group
- Start
- Sep 2013
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Purethal Birch in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Sep 2013; status: completed.
02
Drugs
Purethal Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01918956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01918956.